Visible drug delivery by supramolecular nanocarriers directing to single-platformed diagnosis and therapy of pancreatic tumor model

Cancer Research

Volumn 70, Issue 18, 2010, Pages 7031-7041

  Kaida, Sachiko ^a,d   Cabral, Horacio ^a   Kumagai, Michiaki ^a   Kishimura, Akihiro ^a   Terada, Yasuko ^b   Sekino, Masaki ^a   Aoki, Ichio ^c   Nishiyama, Nobuhiro ^a,c   Tani, Toru ^d   Kataoka, Kazunori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SYNCHROTRON RADIATION RESEARCH INSTITUTE   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^d SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIS(NITRATO) (TRANS L 1,2 DIAMINOCYCLOHEXANE)PLATINUM II; GADOLINIUM PENTETATE; NANOCARRIER; OXALIPLATIN; UNCLASSIFIED DRUG; DICHLORO-1,2-DIAMINOCYCLOHEXANE PLATINUM COMPLEX; MICELLE; NANOPARTICLE; PLATINUM COMPLEX;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHELATION THERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; HUMAN CELL; MICELLE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PANCREAS TUMOR; PRIORITY JOURNAL; X RAY FLUORESCENCE; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIAGNOSTIC USE; INFRARED SPECTROSCOPY; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FEMALE; GADOLINIUM DTPA; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NANOPARTICLES; ORGANOPLATINUM COMPOUNDS; PANCREATIC NEOPLASMS; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 77956926875     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0303     Document Type: Article

References (37)

1. Inoue A, Saijo Y, Maemondo M, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9.
2. Jones BL. Trastuzumab: hopes and realities. Lancet Oncol 2002;3: 137-44.
3. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab- related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005;23:7820-6.
4. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9.
5. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008;7: 771-82.
6. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-60.
7. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotech 2007;2:751-60.
8. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-71.
9. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 2006;6:688-701.
10. Kabanov AV, Alakhov VY. Pluronic block copolymers in drug delivery: from micellar nanocontainers to biological response modifiers. Crit Rev Ther Drug Carrier Syst 2002;19:1-73.
11. Nishiyama N, Kataoka K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol Ther 2006;112:630-48.
12. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009;100:572-9.
13. Hashizume H, Baluk P, Morikawa S, et al. Opening between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000;156:1363-80.
14. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001;41:189-207.
15. Muggia FM, Hainsworth JD, Jeffers S, et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15:987-93.
16. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
17. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986;46:6387-92.
18. Hamaguchi T, Matsumura Y, Shirao K, et al. Phase I study of novel drug delivery system, NK911, a polymer micelle encapsulated doxorubicin [abstract 571]. Proceedings of the 39th annual meeting of the American Society of Clinical Oncology (ASCO); 2003, May 31-June 3; Chicago, USA.
19. Kato K, Hamaguchi T, Yasui H, et al. Phase I study of NK105, a paclitaxel-incorporating micellar nanoparticle, in patients with advanced cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2006;24:2018.
20. Burris HA III, Infante JR, Spigel DR, et al. A phase I dose-escalation study of NK012. ASCO Annual Meeting Proceedings. J Clin Oncol 2008;26:2538.
21. Wilson RH, Plummer R, Adam J, et al. Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles. J Clin Oncol 2008;26:2573.
22. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13:4429-34.
23. McCarthy JR, Weissleder R. Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv Drug Deliv Rev 2008;60: 1241-51.
24. McCarthy JR, Jaffer FA, Weissleder R. A macrophage-targeted theranostic nanoparticle for biomedical applications. Small 2006; 2:983-7.
25. Pan D, Caruthers SD, Hu G, et al. Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J Am Chem Soc 2008;130: 9186-7.
26. Nasongkla N, Bey E, Ren J, et al. Multifunctional polymeric micelles as cancer-targeted, MRI-ultrasensitive drug delivery systems. Nano Lett 2006;6:2427-30.
27. Weinmann HJ, Brasch RC, Press WR, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. Am J Roentgenol 1984;142:619-24.
28. Cabral H, Nishiyama N, Okazaki S, Koyama H, Kataoka K. Preparation and biological properties of dichrolo(1,2-diaminocyclohexane) platinum(II) (DACHPt)-loaded polymeric micelles. J Control Release 2005;101:223-32.
29. Gouin S, Winnik F. Quantitative assays of the amount of diethylene-triaminepentaacetic acid conjugated to water-soluble polymers using isothermal titration calorimetry and colorimetry. Bioconjug Chem 2001;12:372-7.
30. Terada Y, Goto S, Takimoto N, et al. Construction and commissioning of BL37XU at SPring-8. AIP Conf Proc 2004;705:376-9.
31. Ventrucci M, Cipolla A, Racchini C, Casadei R, Simoni P, Gullo L. Tumor M2-pyruvate kinase, a new metabolic marker for pancreatic cancer. Dig Dis Sci 2004;49:1149-55.
32. Jemal A, et al. Cancer statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
33. Sofuni A, et al. Differential diagnosis of pancreatic tumors using ultrasound contrast imaging. J Gastroenterol 2005;40:518-25.
34. Miller FH, Rini NJ, Keppke AL. MRI of adenocarcinoma of the pancreas. Am J Roentgenol 2006;187:W365-374.
35. Zhang Z, Greenfield MT, Spiller M, McMurry TJ, Lauffer RB, Caravan P. Multilocus binding increases the relaxivity of protein-bound MRI contrast agents. Angew Chem 2005;117:6924-7.
36. Livramento JB, Toth E, Sour A, Borel A, Merbach AE, Ruloff R. High relaxivity confined to a small molecular space: a metallostar-based potential MRI contrast agent. Angew Chem Int Ed 2005; 44:1480-4.
37. Duncan R, Izzo L. Dendrimer biocompatibility toxicity. Adv Drug Deliv Rev 2005;57:2215-37.